Biopharma Dealmaking

As external innovation continues to be a critical part of portfolio strategy for the biggest BioPharma players, it drives the deals activity as companies race to license and acquire the assets that will give them market segment dominance. All indications are that 2018 will another mega-dealmaking year as big dollars have flowed forth for licensing and M&A deals in the first half of the year. Using Cortellis tools, our experts delve into these partnerships and M&As to provide attendees with valuable market insights:

• Who has emerged early in the year as the biggest dealmakers
• A breakdown of the top 3 biopharma licensing deals and the top 3 M&A deals
• What therapeutic areas stand out, and why
• A closer examination of the burgeoning Asia Pacific region where dealmakers are more active than ever
• Preview of the biggest deals and outlook for Q3